We are dedicated to research in neurodegenerative diseases and a leader in Alzheimer’s disease research. Our mission is to discover, develop and commercialise innovative products for the diagnosis, treatment and cure of neurodegenerative diseases caused through protein aggregation.
From initial discovery, through preclinical development to clinical trials, regulatory submissions, and product registration, we are harnessing world-class proprietary drug discovery platforms with the aim of halting the progression of Alzheimer’s and other neurodegenerative diseases with our treatments and diagnostics.
Our novel tau aggregation inhibitors (TAIs) target the formation or aggregation of tau protein ‘tangles’ in the brain. The spread of tau tangles is strongly correlated with cognitive decline in dementia and they can develop in the brain up to 20 years before symptoms associated with dementia develop. TAIs work by breaking down existing tau aggregates and preventing the further aggregation of tau protein from forming new tangles.
Our lead compound, hydromethylthionine (known as LMTM or LMTX®), inhibits aggregation of tau, synuclein, TPD-43 and huntingtin proteins. It has shown promise in previous Phase 3 clinical trials for slowing disease progression in Alzheimer’s disease and behavioural variant frontotemporal dementia.
For a summary of the clinical trials programme, the current LUCIDITY trial, and study results, please follow this link.